Disciplined Investments LLC Reduces Stake in Eli Lilly and Company (NYSE:LLY)

Disciplined Investments LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 5.1% during the fourth quarter, Holdings Channel reports. The fund owned 335 shares of the company’s stock after selling 18 shares during the period. Disciplined Investments LLC’s holdings in Eli Lilly and Company were worth $259,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Alley Investment Management Company LLC grew its stake in Eli Lilly and Company by 1.1% in the 4th quarter. Alley Investment Management Company LLC now owns 12,949 shares of the company’s stock worth $9,997,000 after buying an additional 137 shares in the last quarter. Ring Mountain Capital LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $533,000. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Eli Lilly and Company by 38.8% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 8,643 shares of the company’s stock valued at $6,672,000 after purchasing an additional 2,418 shares in the last quarter. Synergy Investment Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $972,000. Finally, Alta Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 1.4% in the 4th quarter. Alta Capital Management LLC now owns 1,014 shares of the company’s stock valued at $783,000 after purchasing an additional 14 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.0 %

NYSE:LLY opened at $930.22 on Tuesday. The firm has a market cap of $882.01 billion, a P/E ratio of 79.44, a P/E/G ratio of 1.40 and a beta of 0.42. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The firm has a 50-day simple moving average of $817.56 and a two-hundred day simple moving average of $848.11.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Eli Lilly and Company announced that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.